DENALI THERAPEUTICS INC (DNLI) Fundamental Analysis & Valuation

NASDAQ:DNLI • US24823R1059

Current stock price

20.57 USD
-0.13 (-0.63%)
At close:
20.5 USD
-0.07 (-0.34%)
After Hours:

This DNLI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DNLI Profitability Analysis

1.1 Basic Checks

  • In the past year DNLI has reported negative net income.
  • DNLI had a negative operating cash flow in the past year.
  • In the past 5 years DNLI always reported negative net income.
  • In the past 5 years DNLI always reported negative operating cash flow.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

1.2 Ratios

  • With a Return On Assets value of -44.77%, DNLI perfoms like the industry average, outperforming 52.90% of the companies in the same industry.
  • DNLI has a better Return On Equity (-50.56%) than 64.67% of its industry peers.
Industry RankSector Rank
ROA -44.77%
ROE -50.56%
ROIC N/A
ROA(3y)-29.37%
ROA(5y)-26.23%
ROE(3y)-33.01%
ROE(5y)-32.1%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40 -50

1.3 Margins

  • DNLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DNLI Health Analysis

2.1 Basic Checks

  • DNLI has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DNLI has been increased compared to 5 years ago.
  • Compared to 1 year ago, DNLI has an improved debt to assets ratio.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • DNLI has an Altman-Z score of 11.66. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of DNLI (11.66) is better than 83.78% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that DNLI is not too dependend on debt financing.
  • DNLI has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 11.66
ROIC/WACCN/A
WACCN/A
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 9.16 indicates that DNLI has no problem at all paying its short term obligations.
  • The Current ratio of DNLI (9.16) is better than 77.41% of its industry peers.
  • DNLI has a Quick Ratio of 9.16. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of DNLI (9.16) is better than 77.41% of its industry peers.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. DNLI Growth Analysis

3.1 Past

  • DNLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.24%.
EPS 1Y (TTM)-11.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DNLI will show a very strong growth in Earnings Per Share. The EPS will grow by 20.63% on average per year.
  • The Revenue is expected to grow by 309.60% on average over the next years. This is a very strong growth
EPS Next Y4.15%
EPS Next 2Y6.97%
EPS Next 3Y18.07%
EPS Next 5Y20.63%
Revenue Next Year3761.96%
Revenue Next 2Y1129.02%
Revenue Next 3Y657.88%
Revenue Next 5Y309.6%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. DNLI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
  • Also next year DNLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DNLI's earnings are expected to grow with 18.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.97%
EPS Next 3Y18.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DNLI Dividend Analysis

5.1 Amount

  • DNLI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DNLI Fundamentals: All Metrics, Ratios and Statistics

DENALI THERAPEUTICS INC

NASDAQ:DNLI (3/13/2026, 8:21:24 PM)

After market: 20.5 -0.07 (-0.34%)

20.57

-0.13 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners98.47%
Inst Owner Change6.06%
Ins Owners4.26%
Ins Owner Change0.69%
Market Cap3.26B
Revenue(TTM)N/A
Net Income(TTM)-512.54M
Analysts87.2
Price Target32.95 (60.18%)
Short Float %9.5%
Short Ratio8.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.66%
Min EPS beat(2)3.5%
Max EPS beat(2)3.82%
EPS beat(4)3
Avg EPS beat(4)-0.56%
Min EPS beat(4)-11.43%
Max EPS beat(4)3.82%
EPS beat(8)5
Avg EPS beat(8)2.79%
EPS beat(12)7
Avg EPS beat(12)25.38%
EPS beat(16)9
Avg EPS beat(16)20.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.25%
PT rev (3m)0.29%
EPS NQ rev (1m)5.47%
EPS NQ rev (3m)6.55%
EPS NY rev (1m)6.39%
EPS NY rev (3m)7.43%
Revenue NQ rev (1m)-72.04%
Revenue NQ rev (3m)-72.11%
Revenue NY rev (1m)-9.84%
Revenue NY rev (3m)-11.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.22
P/tB 3.22
EV/EBITDA N/A
EPS(TTM)-2.97
EYN/A
EPS(NY)-2.85
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS6.39
TBVpS6.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.77%
ROE -50.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.37%
ROA(5y)-26.23%
ROE(3y)-33.01%
ROE(5y)-32.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z 11.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.16%
Cap/Depr(5y)117.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.96%
EPS Next Y4.15%
EPS Next 2Y6.97%
EPS Next 3Y18.07%
EPS Next 5Y20.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year3761.96%
Revenue Next 2Y1129.02%
Revenue Next 3Y657.88%
Revenue Next 5Y309.6%
EBIT growth 1Y-10.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.52%
EBIT Next 3Y3.78%
EBIT Next 5Y29.38%
FCF growth 1Y-16.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.67%
OCF growth 3YN/A
OCF growth 5YN/A

DENALI THERAPEUTICS INC / DNLI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DENALI THERAPEUTICS INC (DNLI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DNLI.


Can you provide the valuation status for DENALI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DENALI THERAPEUTICS INC (DNLI). This can be considered as Overvalued.


How profitable is DENALI THERAPEUTICS INC (DNLI) stock?

DENALI THERAPEUTICS INC (DNLI) has a profitability rating of 1 / 10.


How financially healthy is DENALI THERAPEUTICS INC?

The financial health rating of DENALI THERAPEUTICS INC (DNLI) is 5 / 10.